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Abstract—All types of vascular access, a necessity for
haemodialysis, are prone to thrombosis and if untreated this
results in failure. Thrombosis results from the combination
of impaired blood ﬂow, endothelial and vessel wall injury and
a propensity towards pro-coagulative states, either intrinsic
or aggravated by dialysis or dehydration. The treatment of
access thrombosis relies on removal of the clot (thrombec-
tomy) and treatment of the underlying problem. In most
cases this is stenosis secondary to neointimal hyperplasia
which can occur early (failure to mature) or later. Pharma-
cological approaches have largely been shown to be ineffec-
tive at prevention of thrombosis. The mainstay of preventing
access failure may be in surveillance and detecting stenosis
prior to occlusion although the optimal protocol to achieve
this remains undeﬁned. Management of thrombosed access is
via either surgical and radiological approaches. Multiple
techniques and devices are available for thrombectomy and
the choice is usually based on local expertise and availability
rather than evidence as few trials have been performed to
allow robust comparisons. This paper outlines the basis of
access thrombosis and discusses the currently available
techniques for treatment.
Keywords—Thrombosis, Maturation, Vascular access,
Patency, Arteriovenous ﬁstula.
INTRODUCTION
Haemodialysis vascular access (VA), whether an
autologous arteriovenous ﬁstula (AVF) or a prosthetic
arteriovenous graft (AVG), is prone to thrombosis
which, if untreated, results in failure. Prior to throm-
bosis occurring, ﬁstulas may function normally al-
though those with poor ﬂows or high pressures due to
underlying stenosis are at high risk.15 Following for-
mation a proportion of AVFs fail to mature (FTM)
and are unsuitable for dialysis.1,4 In many studies
FTM is termed thrombosis and should be more accu-
rately deﬁned.24
The pathogenesis of thrombosis results from acti-
vation of the clotting cascade and the factors respon-
sible were ﬁrst described by Virchow in 1888:17
1. Stasis of blood.
2. Blood vessel wall injury.
3. Change in constituents of the blood.
When these are applied to vascular access it is clear
why the occurrence of thrombosis is high and is the
usual eventual fate of both AVFs and AVGs (Table 1).
During surgical creation of VA, there is stasis due to
vascular clamping. There is vessel wall injury sec-
ondary to surgical trauma, clamps and sutures. The
constituents of the blood may be altered with higher
blood viscosity and dehydration from dialysis and
preoperative fasting. Some patients may have pro-co-
agulative tendencies. Chronic kidney disease in itself
has been reported to represent a strong and indepen-
dent risk factor for both spontaneous venous and
arterial (post-vascular injury) thrombosis.17 As a result
primary failure rates are high. Even with successful
post-operative ﬂow the response of the vessel wall to
abnormal ﬂow patterns may result in a neointimal
hyperplastic (NIH) response with progressive stenosis
and resistance to ﬂow with localised stasis.8,14 This
process affects between 20 and 60% of AVFs and
AVGs.3,13,24
Even in established VA the continued eﬀects of
aberrant vascular ﬂow cause stenosis due to NIH and
in association with repeated needling along with
problems such as dehydration and hypotension pre-
dispose to thrombosis and failure.
Clinically many dialysis established patients will be
the ones to make the diagnosis of VA thrombosis as
they no longer feel a thrill within the access. If not, the
dialysis nurses will be unable to use the access at their
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next dialysis session. Final conﬁrmation with sonog-
raphy may be required. The urgency of thrombectomy
is higher in AVFs due to the risk of further endothelial
injury by continued thrombus contact. Theoretically
AVGs can be successfully salvaged up to 2 weeks or
beyond, although the requirement for dialysis would
favour early intervention. Surgical and interventional
radiological techniques are available and may be used
in combination.22
SURGICAL THROMBECTOMY
Surgical thrombectomy in its simplest form involves
open surgical access to the ﬁstula and clot expression
by manual pressure. This is of course a crude technique
with poor results and the introduction of the Fogarty
balloon catheter in 1966 resulted in much improved
outcomes.6 It is recommended that on-table angiogra-
phy should be performed whenever possible to exclude
any stenoses or residual thrombus. If an underlying
cause of thrombosis is identiﬁed, this should be treated
straight away to avoid recurrence of the thrombosis.
Surgical thrombectomy of an AVF can be especially
challenging compared to a graft. It is often difﬁcult to
completely remove thrombus adjacent to the anasto-
mosis of the ﬁstula, and pseudoaneurysms within the
ﬁstula can prevent passage of the thrombectomy ca-
theter or complete removal of thrombus from the ﬁs-
tula.
Studies that have shown improved outcomes from
surgery over radiology tend to include complete revi-
sional surgery of the access rather than true salvage
procedures. Improvements in interventional radiology
(IR) techniques have made the percutaneous modality
to be more favourable. Percutaneous salvage of
thrombosed AVFs has been reported to be a highly
eﬃcient procedure as well as being a signiﬁcantly lower
healthcare cost than surgical intervention.2 A recently
published meta-analysis reported that comparable re-
sults to surgery were achieved with endovascular
techniques for occluded prosthetic grafts for dialysis
access. However long-term data comparing the two
groups was reported to be lacking.7 The best results for
surgical thrombectomy compared to radiological
intervention is found in arteriovenous ﬁstula when the
cause of the thrombosis can be due to anastomotic
stenosis as proximal re-anastomosis can be carried out
to treat the underlying cause at the time of surgery.22
RADIOLOGICAL INTERVENTIONS
Nowadays in most centres IR techniques are the
ﬁrst line due to their minimally invasive nature. There
are a multitude of devices available for percutaneous
intervention for thrombosis with emerging evidence
supporting their application.9,10,18 Endovascular ther-
apy employs a number of different techniques and
these can be divided as follow:
1. Catheter Directed Thrombolysis—The instil-
lation of a lytic agent such as tPA (tissue
plasminogen activator). This techniques allows
the clot to be ‘laced’ with the agent and relying
on it to subsequently dissolve to restore pa-
tency.
2. Mechanical Thrombectomy—There are a num-
ber of mechanical devices available that all work
on the principle of macerating the clot and either
dissipating it within the circulatory system or
subsequently removing it by suction. Some
examples of these include employment of rotat-
ing baskets (Arrow Treratola device, PTD
Arrow—Reading, PA, USA, The CleanerTM
Rotational Thrombectomy System—Rex medi-
cal, Athens, TX, USA) and brushes (Cragg
thrombolytic brush catheter, TBC; MicroTher-
apeutics, Irvine, Calif, USA).5,18
3. Pharmacomechanical—This combines
mechanical thrombectomy with thrombolysis
and has shown to be very effective. An example
of a device that delivers this is the AngioJet
Rheolytic system (Boston Scientiﬁc, MA,
TABLE 1. Factors involved in the pathogenesis of dialysis vascular access thrombosis as described by Virchow’s triad.
Stasis of blood Wall injury Content of blood
At surgery Clamping of vessels
Vessel spasm
Surgical trauma
Clamps
Sutures
uraemia
Dehydration
Post dialysis haemoconcentration
Erythropoietin
Maturation Neointimal hyperplasia
Vein fibrosis due to venepuncture
Pathological flow e.g. turbulence
Uraemia
Diabetes
Procoagulant states
Dialysis Pressure on needle points
Stenosis due to neointimal hyperplasia
Repeated needling
Aberrant flow
Local paracrine factors
Dehydration
Hypotension
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USA).20 Here a high pressure jet of saline
solution (which can be mixed with throm-
bolytic agents) is injected by a pump through a
catheter that is then moved over a wire across
the thrombosed segment of the target vessels.
The high pressure solution fragments the clot
and a negative pressure is created ahead of the
catheter. With the subsequent negative pres-
sure, the fragmented clot is retrieved via the
catheter in its exhaust port. Another recently
available device, the EKOS MicroLysUS
infusion catheter, (EKOS Corporation, Bo-
thell, WA, USA) is based on ultrasound en-
hanced thrombolysis. This device instils tPA
slowly via a very narrow catheter left indwel-
ling in the thrombosed segment. Adjuvant
disruption of the clot is achieved with an
ultrasound cavitation effect.25 This has been
shown to be effective in various settings, vari-
ous settings but little evidence is currently
available for its application in vascular access
thrombosis.16
4. Suction Thrombectomy: This is the removal of
culprit thrombus via a large bore catheter
placed percutaneously within the vessel and
attached manually to a large bore syringe. This
is particularly effective at treating relatively
fresh thrombus.
5. Any combination of the above techniques can
be applied.
Whichever modality is applied for thrombus re-
moval there is always an underlying pathology, usually
a mechanical obstruction causing the thrombosis, such
as a venous stenosis. This needs to be treated at the
same time as clot removal to restore ﬂow in the access
and prevent future re-thrombosis. Balloon angioplasty
is usually eﬀective but high elastic recoil forces in dis-
eased areas often require a stent or stent graft to
maintain and improve patency.23 Stents offer
mechanical radial support in these circumstances but
controversially themselves are also prone to re-nar-
rowing due to intimal hyperplasia and subsequent
thrombosis. Covered stents or stent grafts may avoid
this phenomenon of in-stent NIH. However, these too
are prone to its formation and subsequent stent graft
edge stenosis.
CONCLUSION
Vascular access thrombosis can be treated by both
surgical and radiological thrombectomy. Through
technological advancements, intervention radiology
has become the ﬁrst choice therapy. The beneﬁts of
interventional radiology extend beyond the minimally
invasive approach by allowing visualisation and
treatment of the underlying lesion by angioplasty with
or without stenting. It is for this reason that the out-
comes using such approaches are superior.
Although these treatments are available, it would be
preferable if thrombosis could be prevented. The use of
systemic antithrombotic therapies in vascular access
has not been demonstrated to reduce the inci-
dence.11,12,21 Antiplatelets (aspirin, clopidogrel,
dipyrimadole) have not shown any beneﬁt and formal
anticoagulation with warfarin has shown worse out-
comes. Strategies with coating grafts with heparin
(Propaten) again have not demonstrated statistically
signiﬁcant beneﬁt in vascular access.19 The failure of
these approaches further conﬁrms that thrombosis is
not due to a single factor but is frequently associated
with an underlying lesion and is precipitated by con-
comitant risk factors.
In summary thrombosis remains the main cause of
vascular access failure and although multiple treat-
ments are available, the prevention lies in detecting
stenosis before they become critical.
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